The maintenance of an Overweight rating combined with a raised price target by Keybanc suggests a strong confidence in West Pharmaceutical Services' future performance. The company's significant role in the pharmaceutical and biotech industries, along with its international revenue generation, positions it well for growth. The analyst's upgrade implies a positive outlook, likely influencing investor sentiment and potentially driving the stock price up in the short term.